

## **All MCOs & DMOs: Termination of Planned Parenthood Clinics from Texas Medicaid**

### **Background:**

As of January 4, 2020, Planned Parenthood of North Texas, Planned Parenthood of South Texas and Planned Parenthood Gulf Coast have been terminated as providers in Texas Medicaid. These providers have been notified in writing that they cannot accept any new Medicaid clients and that there will be a 30-day grace period (until February 3, 2021) provided to ensure that their current Medicaid clients can be transitioned to new providers. Please follow your normal procedures to transition these clients to new providers.

### **Key Details:**

The payment denial code (PDC) for these providers is effective February 4, 2021. Claims with dates of service as of this date should be denied as the provider is not enrolled in Texas Medicaid. MCOs should update their systems to deny claims with a date of service after February 3<sup>rd</sup>. The PDC for these providers will be reflected on the master provider file.

### **Contact:**

Please contact your MCCO monitoring team, with copy to Camisha Banks at [camisha.banks@hhs.texas.gov](mailto:camisha.banks@hhs.texas.gov), with question regarding this notice.

---

## **All MCOs: Additional Monoclonal Antibody Therapy Procedure Codes Approved for COVID-19 Treatment**

### **Background:**

Effective December 3, 2020, for dates of service on or after November 9, 2020, procedure codes Q0239 and M0239 have been added for Texas Medicaid.

Effective December 15, 2020, for dates of service on or after November 21, 2020, procedure codes Q0243 and M0243 have been added for Texas Medicaid.

### **Key Details:**

On November 9, 2020, the FDA issued emergency use authorization of the monoclonal antibody therapy drug Bamlanivimab for treatment of mild-to-moderate COVID-19. Effective December 3, 2020, for dates of service on or after November 9, 2020, procedure codes Q0239 (Bamlanivimab) and M0239 (administration of Bamlanivimab) have been added for Texas Medicaid.

On November 21, 2020, the FDA issued emergency use authorization of the monoclonal antibody therapy drug Casirivimab and Imdevimab for treatment of mild-to-moderate COVID-19. Effective December 15, 2020, for dates of service on or after November 21, 2020, procedure codes Q0243 (Casirivimab and Imdevimab) and M0243 (administration of Casirivimab and Imdevimab) have been added for Texas Medicaid.

- Procedure codes Q0239 and Q0243 are informational only while being distributed to providers free of charge.
- Procedure codes M0239 and M0243 are a benefit for clients who are 12 years of age and older, weigh at least 40kg and restricted to diagnosis code U071.
- Procedure code M0239 and M0243 are a benefit for the following providers and places of service:

Office	Physician, Physician Groups, Physician Assistant, Nurse Practitioner, Clinical Nurse Specialist
Outpatient Hospital	Hospital Providers

Denied claims for procedure codes Q0239 and M0239 with dates of service on or after November 9, 2020 and denied claims for procedure codes Q0243 and M0243 with dates of service on or after November 21, 2020, must be automatically reprocessed for appropriate payment no later than March 5, 2021 and providers may receive an additional payment. MCOs should also waive the 95-day filing deadline for any claims that were not submitted prior to these codes being established. No interest is due to providers in either scenario.

**Note:** *Providers are not required to appeal the claims unless they are denied for other reasons after the claims reprocessing is complete.*

**Resources:**

[Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction](#)

**Contact:**

[Suzanne.Lakin@hhsc.state.tx.us](mailto:Suzanne.Lakin@hhsc.state.tx.us)